Neoadjuvant Chemotherapy Plus/Minus Surgery in Non-Small-Cell Lung Cancer (NSCLC) Stage IIIA/N2
Recruitment status was Recruiting
Hypothesis is that surgery is of benefit in locally advanced NSCLC with N2 disease.
Patients are randomised to surgery or not.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Scandinavian Neoadjuvant Phase III Study of Induction Chemotherapy Followed by Irradiation Alone or Surgery Plus Irradiation in NSCLC Stage IIIA/N2 (T1N2, T2N2, T3/N2).|
- time to progression
|Study Start Date:||January 1998|
|Estimated Study Completion Date:||January 2008|
Patients are after staging randomised to neoadj. chemotherapy followed by surgery followed by irradiation or to chemotherapy followed by irradiation.
Endpoint is survival.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00273494
|Contact: Jens B. Sorensen, MDemail@example.com|
|Dept. Oncology, Rigshospitalet||Recruiting|
|Copenhagen, Denmark, 2100|
|Contact: Jens B. Sorensen, MD 35454372 firstname.lastname@example.org|
|Contact: Jens B. Sorensen, MD 35454372 ext email@example.com|
|Principal Investigator: Jens B. Sorensen, MD|
|Study Chair:||Jens B. Sorensen, MD||Rigshospitalet, Denmark|